A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

RecruitingOBSERVATIONAL

Enrollment

250

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Crohn's Disease

Trial Locations (2)

RECRUITING

A.O. Ordine Mauriziano di Torino /ID# 274459, Turin

RECRUITING

IRCCS Istituto Clinico Humanitas /ID# 274489, Rozzano